Targeting Akt reactivation following mTOR inhibition in breast cancer treatment

被引：0
|
作者：
Alayev, Anya [1 ]
Snyder, Rose B. [1 ]
Holz, Marina K. [1 ]
机构：
[1] Yeshiva Univ, New York, NY 10033 USA
来源：
MOLECULAR CANCER RESEARCH | 2013年 / 11卷
关键词：
D O I：
10.1158/1557-3125.ADVBC-A068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A068
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phytochemicals as PI3K/Akt/mTOR Inhibitors and Their Role in Breast Cancer Treatment
    Narayanankutty, Arunaksharan
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2020, 15 (03) : 188 - 199
  • [42] Targeting of the AKT-mTOR pathway in head and neck and lung cancer
    Vignot, S.
    Haberer, S.
    Besse, B.
    BULLETIN DU CANCER, 2009, 96 : S57 - S63
  • [43] Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
    Harsha, Choudhary
    Banik, Kishore
    Ang, Hui Li
    Girisa, Sosmitha
    Vikkurthi, Rajesh
    Parama, Dey
    Rana, Varsha
    Shabnam, Bano
    Khatoon, Elina
    Kumar, Alan Prem
    Kunnumakkara, Ajaikumar B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [44] Targeting stem cells in triple negative breast cancer through combined MEK and AKT inhibition
    Zhang, Kevin
    McDermott, Sean P.
    Wicha, Max S.
    CANCER RESEARCH, 2014, 74 (19)
  • [45] FAK inhibition prevents AKT activation in response to mTOR inhibitors and synergistically inhibits breast cancer growth.
    Vite, Leslie Cuellar
    Bonk, Kristen Weber
    Yori, Jennifer
    Hoffmann, Jennifer
    Keri, Ruth
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 45 - 45
  • [46] AKT and/or mTOR inhibition as a potential target in trastuzumab resistant breast cancer cells with MUC-4 overexpression
    Perez-Fidalgo, J. A.
    Espin, E.
    Tormo, E.
    Pineda, B.
    Cejalvo, J. M.
    Sabbaghi, M. A.
    Alonso, E.
    Rovira, A.
    Rojo, F.
    Albanell, J.
    Bermejo, B.
    Burgues, O.
    Lluch, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S17 - S17
  • [47] mTOR inhibition in hormone-resistant breast cancer
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2012, 13 (06): : E239 - E239
  • [48] Restoration of miR-100 sensitizes luminal A breast cancer to paclitaxel treatment by targeting mTOR
    Zhang, Baotong
    Zhao, Ranran
    He, Yuan
    Fu, Xing
    Dong, Jin-Tang
    CANCER RESEARCH, 2015, 75
  • [49] Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Browne, Iseult M.
    Andre, Fabrice
    Chandarlapaty, Sarat
    Carey, Lisa A.
    Turner, Nicholas C.
    LANCET ONCOLOGY, 2024, 25 (04): : e139 - e151
  • [50] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
    Angel Guerrero-Zotano
    Ingrid A. Mayer
    Carlos L. Arteaga
    Cancer and Metastasis Reviews, 2016, 35 : 515 - 524
12345